- Home
- CYH vs ZURA Comparison
CYH vs ZURA Comparison
Compare CYH & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | ZURA |
|---|---|---|
| Founded | 1985 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 455.4M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYH | ZURA |
|---|---|---|
| Price | $2.93 | $5.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.28 | ★ $13.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $12,485,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.17 | N/A |
| P/E Ratio | $32.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.41 | $1.88 |
| 52 Week High | $4.43 | $7.25 |
Technical Indicators
Market Signals| Indicator | CYH | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 50.88 |
| Support Level | $2.84 | $5.22 |
| Resistance Level | $2.99 | $5.87 |
| Average True Range (ATR) | 0.09 | 0.36 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 47.06 | 18.90 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.